INVO

Naya Biosciences Inc. (INVO) | Rumor.io

Naya Biosciences

INVO

Attention (50-day avg)0%

Attention rank (50-day avg)#4,226

Bullish sentiment (50-day avg)100%

Price to earnings ratio1.21

Market capitalization2.4M

Earnings per share-5.13

Dividend yield (TTM)—

Revenue (annual)3M

Net income (annual)-8M

Social

What share of all stock conversation is about INVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 4

INVO Bioscience, Inc. (INVO) has received substantial consummation and is out of bankruptcy, with 12 months to go from the last date of importance.
The company's deal with Alexion has been approved, and there is a revolving facility that will take another 12 months, with carve-outs expected to make things interesting.
INVO's ulcerative colitis trial has been terminated, and the company has dissolved its subsidiary, Immune Pharmaceuticals of Nevada, with the Chapter 7 case closed.

Generated by AI

Sentiment

Of the messages about INVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.93% +15.14
Bearish	—	—	—	1.07% -15.14

Bullish· Jan 19

INVO Bioscience, Inc. has the potential for a big breakout to the upside, with a strong accumulation pattern on its chart.
The company is well-positioned to capitalize on the massive $10B affiliate market, bringing decentralized and low-cost payments to the Web3 space.
INVO's professional team and real e-commerce solutions, including low fees, no censorship, and Web3 speed, make it an undervalued play with significant growth potential.

Bearish· Apr 17

The stock has a history of consecutive lower highs, indicating a potential bearish trend.
The company's warrants were repriced, which may have led to a significant decrease in the stock's value.
The stock has a small float, lacks working capital and cash, and relies heavily on active warrants, making it vulnerable to market fluctuations.

Generated by AI

Topics

Of the messages about INVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	100%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Oct 14

INVO Bioscience completed its merger with NAYA Biosciences, acquiring all outstanding equity interests, and expects to change its name to NAYA Biosciences.
The combined company will trade on the Nasdaq under the $NAYA ticker symbol, following the completion of the merger.
INVO Bioscience and NAYA Biosciences have closed the merger, with the combined company to operate as NAYA Biosciences, and a private offering is planned at a target price of $5.00 per common share.

Technical Analysis· Apr 17

$INVO RSI is cooling off, potentially leading to consolidation and a next leg up.
$INVO is trading near the top end of the daily range, with a potential squeeze and swing trade opportunity.
$INVO has a falling wedge breakout, but requires clearing $3.05 resistance for a strong upward move.

Generated by AI

Community

Of the messages about INVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	26.69%
Newcomers	—	—	0%	73.31%

Regulars· Oct 14

$INVO has seen a significant price increase, spiking from $1.15 to $1.90 and reaching as high as $1.90 in after-hours trading, with some participants celebrating the rise.
The stock's low float has been a subject of discussion, with some participants noting its potential for further price appreciation, citing a daily gap that could be filled at $1.70.
A recent development in the biotech sector may have implications for $INVO, as a major player, H. Lundbeck A/S, agreed to acquire another biotech company, Longboard Pharmaceuticals Inc, in a $2.6 billion deal.

Newcomers· Apr 18

New traders are focusing on short-term gains, with one user selling INVO at 2.65 and another cutting losses on a short position.
Some users are struggling to understand the market dynamics of INVO, with one newcomer mentioning missing a short opportunity due to lack of analysis.
There is concern among new traders about the actions of INVO's CEO, Steven Shum, and the potential impact on new investors.

Generated by AI

Also Discussed

Investors talking about INVO also mention

#	Name	Attention
1	Apollomics Inc.APLM	0%0
2	PaxMedica Inc.PXMD	0%0
3	Cardio Diagnostics Holdings, Inc.CDIO	0%0
4	American BriVision (Holding) CorporationABVC	0%+0
5	SECO - Secoo Holding Limited	——
6	MINM - Minim, Inc.	——
7	Tempest Therapeutics Inc.TPST	0%+0
8	ICCT - iCoreConnect Inc.	——
9	Sera Prognostics, Inc. Class A Common StockSERA	0%0
10	ParaZero Technologies Ltd.PRZO	0%+0

Naya Biosciences Inc.

Healthcare
Medical Devices

Naya Biosciences Inc. is an innovative biotechnology company specializing in advanced medical therapies and drug development. Focused on discovering and developing novel treatments for rare and life-threatening conditions, Naya Biosciences plays a critical role in improving patient outcomes across several medical fields. The company's pipeline is composed of therapies targeting genetic disorders, rare diseases, and unmet medical needs, leveraging cutting-edge technologies such as gene editing and precision medicine. With a strong commitment to research and development, Naya Biosciences often collaborates with academic institutions and pharmaceutical partners to accelerate the transition of experimental treatments from bench to bedside. Headquartered in a strategic location to facilitate collaboration and access to research talent, Naya Biosciences is crucial in reshaping the landscape of modern medicine, providing hope for patients worldwide through pioneering therapies that address significant health challenges.

Website

Location

5582 Broadcast Court

Sarasota, FL, 34240

United States

Social

What share of all stock conversation is about INVO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 4

INVO Bioscience, Inc. (INVO) has received substantial consummation and is out of bankruptcy, with 12 months to go from the last date of importance.
The company's deal with Alexion has been approved, and there is a revolving facility that will take another 12 months, with carve-outs expected to make things interesting.
INVO's ulcerative colitis trial has been terminated, and the company has dissolved its subsidiary, Immune Pharmaceuticals of Nevada, with the Chapter 7 case closed.

Generated by AI

Sentiment

Of the messages about INVO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.93% +15.14
Bearish	—	—	—	1.07% -15.14

Bullish· Jan 19

INVO Bioscience, Inc. has the potential for a big breakout to the upside, with a strong accumulation pattern on its chart.
The company is well-positioned to capitalize on the massive $10B affiliate market, bringing decentralized and low-cost payments to the Web3 space.
INVO's professional team and real e-commerce solutions, including low fees, no censorship, and Web3 speed, make it an undervalued play with significant growth potential.

Bearish· Apr 17

The stock has a history of consecutive lower highs, indicating a potential bearish trend.
The company's warrants were repriced, which may have led to a significant decrease in the stock's value.
The stock has a small float, lacks working capital and cash, and relies heavily on active warrants, making it vulnerable to market fluctuations.

Generated by AI

Topics

Of the messages about INVO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	100%
Analysts	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Oct 14

INVO Bioscience completed its merger with NAYA Biosciences, acquiring all outstanding equity interests, and expects to change its name to NAYA Biosciences.
The combined company will trade on the Nasdaq under the $NAYA ticker symbol, following the completion of the merger.
INVO Bioscience and NAYA Biosciences have closed the merger, with the combined company to operate as NAYA Biosciences, and a private offering is planned at a target price of $5.00 per common share.

Technical Analysis· Apr 17

$INVO RSI is cooling off, potentially leading to consolidation and a next leg up.
$INVO is trading near the top end of the daily range, with a potential squeeze and swing trade opportunity.
$INVO has a falling wedge breakout, but requires clearing $3.05 resistance for a strong upward move.

Generated by AI

Community

Of the messages about INVO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	26.69%
Newcomers	—	—	0%	73.31%

Regulars· Oct 14

$INVO has seen a significant price increase, spiking from $1.15 to $1.90 and reaching as high as $1.90 in after-hours trading, with some participants celebrating the rise.
The stock's low float has been a subject of discussion, with some participants noting its potential for further price appreciation, citing a daily gap that could be filled at $1.70.
A recent development in the biotech sector may have implications for $INVO, as a major player, H. Lundbeck A/S, agreed to acquire another biotech company, Longboard Pharmaceuticals Inc, in a $2.6 billion deal.

Newcomers· Apr 18

New traders are focusing on short-term gains, with one user selling INVO at 2.65 and another cutting losses on a short position.
Some users are struggling to understand the market dynamics of INVO, with one newcomer mentioning missing a short opportunity due to lack of analysis.
There is concern among new traders about the actions of INVO's CEO, Steven Shum, and the potential impact on new investors.

Generated by AI

Naya Biosciences

Social

Feb 4

Sentiment

Bullish· Jan 19

Bearish· Apr 17

Topics

Announcements· Oct 14

Technical Analysis· Apr 17

Community

Regulars· Oct 14

Newcomers· Apr 18

Also Discussed

Naya Biosciences Inc.

Company Information

Location

Also Discussed

Social

Feb 4

Sentiment

Bullish· Jan 19

Bearish· Apr 17

Topics

Announcements· Oct 14

Technical Analysis· Apr 17

Community

Regulars· Oct 14

Newcomers· Apr 18